Press releases

2
Feb 2023
21:19 E.S.T.

Cellectis Announces Launch of Follow-On Offering

Read more
20
Jan 2023
21:30 E.S.T.

Cellectis Amends $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics

Read more
17
Jan 2023
12:10 E.S.T.

Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement

Read more
4
Jan 2023
22:00 E.S.T.

Cellectis Establishes an At-The-Market (ATM) Program on Nasdaq

Read more
29
Dec 2022
21:30 E.S.T.

Mayflower Bioventures Launches its First Spin-Out, Primera Therapeutics, in Strategic Collaboration with Cellectis to Develop a Gene Editing Platform to Treat Mitochondrial Diseases

Read more
28
Dec 2022
17:59 E.S.T.

Cellectis secures a €40 million credit facility from the European Investment Bank to support its Research, Development and Innovation activities

Read more
22
Dec 2022
21:30 E.S.T.

Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL

Read more
13
Dec 2022
12:30 E.S.T.

Cellectis Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML

Read more
1
Dec 2022
21:30 E.S.T.

Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022

Read more
10
Nov 2022
14:05 E.S.T.

Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022

Read more

Press contacts

For more information on any story, or for press enquiries, get in touch with our communication team

CONTACT US